131 related articles for article (PubMed ID: 33785258)
1. The capacity of CD4
Holmen Olofsson G; Pedersen SR; Aehnlich P; Svane IM; Idorn M; Thor Straten P
Cytotherapy; 2021 Jul; 23(7):582-589. PubMed ID: 33785258
[TBL] [Abstract][Full Text] [Related]
2. Vγ9Vδ2 T Cells Concurrently Kill Cancer Cells and Cross-Present Tumor Antigens.
Holmen Olofsson G; Idorn M; Carnaz Simões AM; Aehnlich P; Skadborg SK; Noessner E; Debets R; Moser B; Met Ö; Thor Straten P
Front Immunol; 2021; 12():645131. PubMed ID: 34149689
[TBL] [Abstract][Full Text] [Related]
3. Large-scale expansion of Vγ9Vδ2 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor-modified effector cells.
Xiao L; Chen C; Li Z; Zhu S; Tay JC; Zhang X; Zha S; Zeng J; Tan WK; Liu X; Chng WJ; Wang S
Cytotherapy; 2018 Mar; 20(3):420-435. PubMed ID: 29402645
[TBL] [Abstract][Full Text] [Related]
4. Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
Zysk A; DeNichilo MO; Panagopoulos V; Zinonos I; Liapis V; Hay S; Ingman W; Ponomarev V; Atkins G; Findlay D; Zannettino A; Evdokiou A
Cancer Lett; 2017 Feb; 386():141-150. PubMed ID: 27865798
[TBL] [Abstract][Full Text] [Related]
5. Human Vγ9Vδ2 T cells show potent antitumor activity against zoledronate-sensitized OSCC cell lines.
Domae E; Hirai Y; Ikeo T; Goda S; Tsuji K
J BUON; 2018 Dec; 23(7):132-138. PubMed ID: 30722122
[TBL] [Abstract][Full Text] [Related]
6. Antigen-Presenting Cell Characteristics of Human γδ T Lymphocytes in Chronic Myeloid Leukemia.
Sawaisorn P; Tangchaikeeree T; Chan-On W; Leepiyasakulchai C; Udomsangpetch R; Hongeng S; Jangpatarapongsa K
Immunol Invest; 2019 Jan; 48(1):11-26. PubMed ID: 30321079
[TBL] [Abstract][Full Text] [Related]
7. Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma.
Viey E; Fromont G; Escudier B; Morel Y; Da Rocha S; Chouaib S; Caignard A
J Immunol; 2005 Feb; 174(3):1338-47. PubMed ID: 15661891
[TBL] [Abstract][Full Text] [Related]
8. Ex vivo expanded human Vgamma9Vdelta2+ gammadelta-T cells mediate innate antitumor activity against human prostate cancer cells in vitro.
Liu Z; Guo BL; Gehrs BC; Nan L; Lopez RD
J Urol; 2005 May; 173(5):1552-6. PubMed ID: 15821484
[TBL] [Abstract][Full Text] [Related]
9. Activation of Human γδ T Cells: Modulation by Toll-Like Receptor 8 Ligands and Role of Monocytes.
Serrano R; Wesch D; Kabelitz D
Cells; 2020 Mar; 9(3):. PubMed ID: 32183240
[TBL] [Abstract][Full Text] [Related]
10. Values for αβ and γδ T-lymphocytes and CD4+, CD8+, and CD56+ subsets in healthy adult subjects: assessment by age and gender.
Andreu-Ballester JC; García-Ballesteros C; Benet-Campos C; Amigó V; Almela-Quilis A; Mayans J; Ballester F
Cytometry B Clin Cytom; 2012 Jul; 82(4):238-44. PubMed ID: 22539222
[TBL] [Abstract][Full Text] [Related]
11. Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours.
Nicol AJ; Tokuyama H; Mattarollo SR; Hagi T; Suzuki K; Yokokawa K; Nieda M
Br J Cancer; 2011 Sep; 105(6):778-86. PubMed ID: 21847128
[TBL] [Abstract][Full Text] [Related]
12. Releasing the restraints of Vγ9Vδ2 T-cells in cancer immunotherapy.
Ridgley LA; Caron J; Dalgleish A; Bodman-Smith M
Front Immunol; 2022; 13():1065495. PubMed ID: 36713444
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-18 activates Vγ9Vδ2
Murday AS; Chaudhry S; Pauza CD
Immunology; 2017 Aug; 151(4):385-394. PubMed ID: 28342224
[TBL] [Abstract][Full Text] [Related]
14. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo.
Benzaïd I; Mönkkönen H; Stresing V; Bonnelye E; Green J; Mönkkönen J; Touraine JL; Clézardin P
Cancer Res; 2011 Jul; 71(13):4562-72. PubMed ID: 21646473
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic gammadelta or alphabeta T cells with a natural killer cell marker, CD56, induced from human peripheral blood lymphocytes by a combination of IL-12 and IL-2.
Satoh M; Seki S; Hashimoto W; Ogasawara K; Kobayashi T; Kumagai K; Matsuno S; Takeda K
J Immunol; 1996 Nov; 157(9):3886-92. PubMed ID: 8892619
[TBL] [Abstract][Full Text] [Related]
16. Cytokine-mediated activation of human ex vivo-expanded Vγ9Vδ2 T cells.
Domae E; Hirai Y; Ikeo T; Goda S; Shimizu Y
Oncotarget; 2017 Jul; 8(28):45928-45942. PubMed ID: 28521284
[TBL] [Abstract][Full Text] [Related]
17. Human Vγ9Vδ2 T cell expansion and their cytotoxic responses against cholangiocarcinoma.
Sawaisorn P; Gaballa A; Saimuang K; Leepiyasakulchai C; Lertjuthaporn S; Hongeng S; Uhlin M; Jangpatarapongsa K
Sci Rep; 2024 Jan; 14(1):1291. PubMed ID: 38221530
[TBL] [Abstract][Full Text] [Related]
18. TCR repertoire analysis reveals phosphoantigen-induced polyclonal proliferation of Vγ9Vδ2 T cells in neonates and adults.
Fichtner AS; Bubke A; Rampoldi F; Wilharm A; Tan L; Steinbrück L; Schultze-Florey C; von Kaisenberg C; Prinz I; Herrmann T; Ravens S
J Leukoc Biol; 2020 Jun; 107(6):1023-1032. PubMed ID: 32064671
[TBL] [Abstract][Full Text] [Related]
19. IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy.
Thedrez A; Harly C; Morice A; Salot S; Bonneville M; Scotet E
J Immunol; 2009 Mar; 182(6):3423-31. PubMed ID: 19265120
[TBL] [Abstract][Full Text] [Related]
20. Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients.
Viey E; Lucas C; Romagne F; Escudier B; Chouaib S; Caignard A
J Immunother; 2008 Apr; 31(3):313-23. PubMed ID: 18317356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
